CTLA4 and cancer: Immune-checkpoint inhibitors, such as antibodies targeting PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), have shown success in unleashing the immune system against cancer cells.